LIFITEGRAST (lifitegrast) by Bausch + Lomb is lymphocyte function-associated antigen-1 antagonists [moa]. First approved in 2023.
Drug data last refreshed 19h ago
Lymphocyte Function-Associated Antigen-1 Antagonists
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
This is a Single Center, Open-label Prospective Study to Evaluate the Effect of Xiidra® (Lifitegrast Ophthalmic Solution 5.0%) on Tear Film Biomarkers in Dry Eye
A Study to Assess the Long-Term Safety of Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination in Subjects With Dry Eye Disease
Lifitegrast Eye Drops in Healthy Subjects：Phase I Study
The Effects and Safety of 5% Lifitegrast Ophthalmic Solution in Subjects With Dry Eye Disease in Ocular Graft-versus-Host Disease
Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers
Worked on LIFITEGRAST at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.